Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Bossen

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Scandinavian Journal of Gastroenterology|December 18, 2025
Association between quality of life and inflammation and fibrosis markers in primary biliary cholangitis over three-year follow-upMatias Hauge Böttcher, Lars Bossen, Anders Mellemkjær, et al.
Scandinavian Journal of Clinical and Laboratory Investigation|September 21, 2022
Association between fibrosis markers and kidney function following peptide receptor radionuclide therapy in patients with neuroendocrine tumoursTobias Stemann Lau, Lars Bossen, Daniel Guldager Kring Rasmussen, et al.
Frontiers in Endocrinology|July 14, 2025
Fibrosis markers as prognostic markers of decline in kidney function in patients with neuroendocrine neoplasms undergoing peptide receptor radionuclide therapyTobias Stemann Lau, Lars Bossen, Daniel Guldager Kring Rasmussen, et al.
Clinical and Translational Gastroenterology|March 1, 2021
Circulating Macrophage Activation Markers Predict Transplant-Free Survival in Patients With Primary Sclerosing CholangitisLars Bossen, Mette Vesterhus, Johannes R Hov, et al.
Journal of Clinical and Translational Hepatology|October 28, 2022
Highly Increased Levels of Inter-α-inhibitor Heavy Chain 4 (ITIH4) in Autoimmune Cholestatic Liver DiseasesTea Lund Laursen, Lars Bossen, Rasmus Pihl, et al.
Gastro Hep Advances|May 25, 2026
Quality of Life in Patients With Primary Sclerosing CholangitisEmilie Eifer Møller, Rasmus Hvidbjerg Gantzel, Emma Celia Herting, et al.
Journal of Gastroenterology and Hepatology|June 2, 2020
Improved prediction of mortality by combinations of inflammatory markers and standard clinical scores in patients with acute-on-chronic liver failure and acute decompensationHenning Grønbaek, Holger Jon Møller, Faouzi Saliba, et al.
Hepatology Communications|March 27, 2023
The association between soluble CD163, disease severity, and ursodiol treatment in patients with primary biliary cholangitisLars Bossen, Tobias Stemann Lau, Mette Bak Nielsen, et al.
The Turkish Journal of Gastroenterology : the Official Journal of Turkish Society of Gastroenterology|April 4, 2025
Clinical and Biochemical Characteristics of a Danish and Turkish Cohort of Incident and Prevalent Patients with Primary Biliary CholangitisHasan Eruzun, Lars Bossen, Dilara Turan Gökçe, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 13, 2020
Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitisLars Bossen, Paola Rebora, Francesca Bernuzzi, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Scandinavian Journal of Gastroenterology|December 18, 2025
Association between quality of life and inflammation and fibrosis markers in primary biliary cholangitis over three-year follow-upMatias Hauge Böttcher, Lars Bossen, Anders Mellemkjær, et al.
Scandinavian Journal of Clinical and Laboratory Investigation|September 21, 2022
Association between fibrosis markers and kidney function following peptide receptor radionuclide therapy in patients with neuroendocrine tumoursTobias Stemann Lau, Lars Bossen, Daniel Guldager Kring Rasmussen, et al.
Frontiers in Endocrinology|July 14, 2025
Fibrosis markers as prognostic markers of decline in kidney function in patients with neuroendocrine neoplasms undergoing peptide receptor radionuclide therapyTobias Stemann Lau, Lars Bossen, Daniel Guldager Kring Rasmussen, et al.
Clinical and Translational Gastroenterology|March 1, 2021
Circulating Macrophage Activation Markers Predict Transplant-Free Survival in Patients With Primary Sclerosing CholangitisLars Bossen, Mette Vesterhus, Johannes R Hov, et al.
Journal of Clinical and Translational Hepatology|October 28, 2022
Highly Increased Levels of Inter-α-inhibitor Heavy Chain 4 (ITIH4) in Autoimmune Cholestatic Liver DiseasesTea Lund Laursen, Lars Bossen, Rasmus Pihl, et al.
Gastro Hep Advances|May 25, 2026
Quality of Life in Patients With Primary Sclerosing CholangitisEmilie Eifer Møller, Rasmus Hvidbjerg Gantzel, Emma Celia Herting, et al.
Journal of Gastroenterology and Hepatology|June 2, 2020
Improved prediction of mortality by combinations of inflammatory markers and standard clinical scores in patients with acute-on-chronic liver failure and acute decompensationHenning Grønbaek, Holger Jon Møller, Faouzi Saliba, et al.
Hepatology Communications|March 27, 2023
The association between soluble CD163, disease severity, and ursodiol treatment in patients with primary biliary cholangitisLars Bossen, Tobias Stemann Lau, Mette Bak Nielsen, et al.
The Turkish Journal of Gastroenterology : the Official Journal of Turkish Society of Gastroenterology|April 4, 2025
Clinical and Biochemical Characteristics of a Danish and Turkish Cohort of Incident and Prevalent Patients with Primary Biliary CholangitisHasan Eruzun, Lars Bossen, Dilara Turan Gökçe, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 13, 2020
Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitisLars Bossen, Paola Rebora, Francesca Bernuzzi, et al.
Pageof 3